NCT03359499

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients - a Pilot Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Hospital Britanico · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Probiotics have been proposed as useful therapeutic alternatives for the treatment of irritable bowel syndrome patients. Bacillus clausii is a probiotic that has been used for the treatment of acute diarrhea among adults and pediatric patients, as well as an adjunctive therapy for the treatment for Helicobacter pylori infection. It has been proposed that Bacillus clausii is effective for the treatment of irritable bowel syndrome-related symptoms (especially diarrhea and bloating) in non-controlled trials. The aim of the proposed investigation is to determine whether the administration of Bacillus clausii during two weeks plus dietary advice compared to antispasmodics plus dietary advice would be an effective and safe alternative.

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Bacillus clausii	Oral suspension administered BID
DRUG	Trimebutine	One tablet of 200 mg of trimebutine administered BID

Timeline

• Start date: 2017-08-12
• Primary completion: 2017-10-25
• Completion: 2017-11-23
• First posted: 2017-12-02
• Last updated: 2018-03-13

Locations

1 site across 1 country: Argentina